|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Burden of Clostridium difficile infection between 2010 and 2013:Trends and outcomes from an academic center in Eastern Europe显示文摘AIM:To analyze the incidence and possible risk factors in hospitalized patients treated with Clostridium difficile infection(CDI).METHODS:A total of 11751 patients were admitted to our clinic between 1 January 2010 and 1 May2013.Two hundred and forty-seven inpatients were prospectively diagnosed with CDI.For the risk analysis a 1:3 matching was used.Data of 732 patients matched for age,sex,and inpatient care period and unit were compared to those of the CDI population.Inpatient records were collected from an electronic hospital database and comprehensively reviewed.RESULTS:Incidence of CDI was 21.0/1000 admissions(2.1%of all-cause hospitalizations and 4.45%of total inpatient days).The incidence of severe CDI was 12.6%(2.63/1000 of all-cause hospitalizations).Distribution of CDI cases was different according to the unit type,with highest incidence rates in hematology,gastroenterology and nephrology units(32.9,25 and24.6/1000 admissions,respectively) and lowest rates in 1.4%(33/2312) in endocrinology and general internal medicine(14.2 and 16.9/1000 admissions)units.Recurrence of CDI was 11.3%within 12 wk after discharge.Duration of hospital stay was longer in patients with CDI compared to controls(17.6 ± 10.8d vs 12.4 ± 7.71 d).CDI accounted for 6.3%of allinpatient deaths,and 30-d mortality rate was 21.9%(54/247 cases).Risk factors for CDI were antibiotic therapy[including third-generation cephalosporins or fluoroquinolones,odds ratio(OR) = 4.559;P < 0.001],use of proton pump inhibitors(OR = 2.082,P< 0.001),previous hospitaiization within 12 mo(OR = 3.167,P < 0.001),previous CDI(OR = 15.32;P < 0.001),while presence of diabetes mellitus was associated with a decreased risk for CDI(OR = 0.484;P< 0.001).Treatment of recurrent cases was significantly different from primary infections with more frequent use of vancomycin alone or in combination(P < 0.001),and antibiotic therapy duration was longer(P < 0.02).Severity,mortality and outcome of primary infections and relapsing cases did not significantly differ.CONCLUSION:CDI was accounted for significant burden with longer hospitaiization and adverse outcomes.Antibiotic,PPI therapy and previous hospitaiization or CDI were risk factors for CDI. | Zsuzsanna Kurti Barbara D Lovasz Michael D Mandel Zoltan Csima Petra A Golovics Bence D Csako Anna Mohas Lorant Gnczi Krisztina B Gecse Lajos S Kiss Miklos Szathmari Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，21： | 6 |
| 2 | Biological therapy in inflammatory bowel diseases:Access in Central and Eastern Europe显示文摘Biological drugs opened up new horizons in the management of inflammatory bowel diseases(IBD).This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European(CEE)countries,namely Bulgaria,the Czech Republic,Estonia,Hungary,Latvia,Lithuania,Poland,Romania and Slovakia.Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed.Moreover,we provide an estimation on prevalence of IBD as well as biological treatment rates.In all countries with the exception of Romania,lower biological treatment rates were observed in ulcerative colitis(UC)compared to Crohn’s disease despite the higher prevalence of UC.Great heterogeneity(up to 96-fold)was found in access to biologicals across the CEE countries.Poland,Bulgaria,Romania and the Baltic States are lagging behind Hungary,Slovakia and the Czech Republic in their access to biologicals.Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria,Latvia,Lithuania,and Poland,but association with other possible determinants(differences in prevalence and incidence,price of biologicals,total expenditure on health,geographical access,and cost-effectiveness results)was not proven.We assume,nevertheless,that healthdeterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD.In conclusion,access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors,drug prices or total health expenditure.Changes in reimbursement policy could contribute to better access to biologicals in some countries. | Fanni Rencz Márta Péntek Martin Bortlik Edyta Zagorowicz Tibor Hlavaty Andrzej Sliwczyński Mihai M Diculescu Limas Kupcinskas Krisztina B Gecse László Gulácsi Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，6： | 4 |
| 3 | Detailed esophageal function and morphological analysis shows high prevalence of gastroesophageal reflux disease and Barrett’s esophagus in patients with cervical inlet patch显示文摘 | A. Rosztóczy F. Izbéki I. B. Németh S. Dulic K. Vadászi R. Róka K. Gecse T. Gy?keres G. Lázár L. Tiszlavicz T. Wittmann | 2011 | Diseases of the Esophagus2011，，6： | 2 |
| 4 | Increased faecal serine pro- tease activity in diarrhoeic IBS patients: a colonic luminal factor impairing colonic permeability and sensitivity显示文摘 | Gecse K Roka R Ferrier L | 2008 | Gut2008，57，5： | 1 |
| 5 | Increased faecal serine prote- ase activity in diarrhoeic IBS patients: a colonic lumenal factor im- pairing colonic permeability and sensitivity 显示文摘 | Gecse KI R6ka R Ferrier L | 2008 | Gut2008，57，5： | 1 |
| 6 | Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice显示文摘 | Anita Annaházi Krisztina Gecse Marta Dabek Afifa Ait-Belgnaoui András Rosztóczy Richárd Róka Tamás Molnár Vassilia Theodorou Tibor Wittmann Lionel Bueno Helene Eutamene | 2009 | Pain2009，，1： | 1 |
| 7 | Increased faecal serine prote- ase activity in diarrhoeic IBS patients : a colonic lumenal factor im- pairing colonic permeability and sensitivity 显示文摘 | Gecse K Róka R Ferrier L | 2008 | Gut2008，57，5： | 1 |
| 8 | Impact of disease location on fecal calprotectin levels in Crohn’s disease显示文摘 | Krisztina B. Gecse Johannan F. Brandse Sandra van Wilpe Mark Lö wenberg Cyriel Ponsioen Gijs van den Brink Geert D’ Haens | 2015 | Scandinavian Journal of Gastroenterology2015，，7： | 1 |
| 9 | Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity 显示文摘 | Gecse K Rrka R Ferrier L | 2008 | Gut2008，57，5： | 1 |
| 10 | Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort显示文摘 | Zsuzsanna Vegh Petra Anna Golovics Barbara Dorottya Lovasz Zsuzsanna Kurti Krisztina Barbara Gecse Istvan Szita Mihaly Balogh Tunde Pandur Laszlo Lakatos Peter Laszlo Lakatos | 2014 | Scandinavian Journal of Gastroenterology2014，，3： | 1 |
| 11 | Biosimilars in IBD: hope or expectation?显示文摘 | Gecse K B Khanna R van den Brink G R | 2013 | Gut2013，62，6： | 1 |
| 12 | Increased faecal ser- ine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensi- tivity显示文摘 | Gecse K Roka R Ferrier L | 2008 | Gut2008，57，5： | 1 |
| 13 | Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice显示文摘 | Anita Annaházi Krisztina Gecse Marta Dabek Afifa Ait-Belgnaoui András Rosztóczy Richárd Róka Tamás Molnár Vassilia Theodorou Tibor Wittmann Lionel Bueno Helene Eutamene | 2009 | Pain2009，，1： | 1 |
| 14 | A global consensus on the classification,diagnosis and multidisciplinary treatment of perianal fistulising CrohrTs disease显示文摘 | Gecse KB Bemelman W Kamm MA | 2014 | Gut2014，63，9： | 1 |
| 15 | Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice显示文摘 | Annahazi A Gecse K Dabek M | 2009 | Pain2009，144，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员